SCHEMBL22323924

SCHEMBL22323924

COCOc1cc(C#N)ccc1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.40
AR P10275 3/20 0.39
EGFR P00533 2/20 0.37
PIK3CD O00329 1/20 0.37
ABL1 P00519 1/20 0.37
HCK P08631 1/20 0.37
SRC P12931 1/20 0.37
KDR P35968 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
MTOR P42345 1/20 0.37
PIK3CG P48736 1/20 0.37
EPHB4 P54760 1/20 0.37
PRKDC P78527 1/20 0.37
XDH P47989 1/20 0.36
ERBB2 P04626 1/20 0.36
SLC6A4 P31645 2/20 0.35
ALK Q9UM73 1/20 0.34
EGLN2 Q96KS0 1/20 0.34
HTR2A P28223 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29886939 0.87 FFAR1 (0.40) TRPV4AREGFRXDHERBB2
SCHEMBL28833261 0.87 FFAR1 (0.40) TRPV4AREGFRXDHERBB2
SCHEMBL31314271 0.85 TRPV4 (0.46) TRPV4ARHTR2AKCNH2FFAR1
SCHEMBL15170403 0.84 AR (0.45) TRPV4ARXDHSLC6A4EGLN2
SCHEMBL29710928 0.83 TRPV4 (0.56) TRPV4AR
SCHEMBL14472635 0.83 AR (0.50) TRPV4ARXDHEGLN2HTR2A
SCHEMBL28691150 0.83 TRPV4 (0.33) TRPV4ALK
SCHEMBL1734101 0.81 AR (0.54) TRPV4ARXDHSLC6A4EGLN2
SCHEMBL31014083 0.81 XDH (0.36) TRPV4AREGFRXDHERBB2
SCHEMBL30376409 0.80 AR (0.51) ARSLC6A4ALKEGLN2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 US disclosed
US-20240262806-A1 INHIBITORS OF NLRP3 PCT THERAPEUTICS, INC. (US) 2024-08-08 US disclosed
CN-118302417-A NLRP3 inhibitors PTC医疗公司 2024-07-05 CN disclosed
EP-4392414-A1 INHIBITORS OF NLRP3 PTC Therapeutics, Inc. (US) 2024-07-03 EP disclosed
WO-2023028534-A1 INHIBITORS OF NLRP3 PTC THERAPEUTICS, INC. (US) 2023-03-02 WO disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 US disclosed
CN-114126613-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-03-01 CN disclosed
WO-2022031998-A2 PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE PREPARATION OF COMPOUNDS THAT MODULATE SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2022-02-10 WO disclosed
EP-3920926-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2021-12-15 EP disclosed
WO-2020163541-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 TRPV4 4722/4885AR 3915/4885EGFR 4860/4885
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 TRPV4 4784/4885AR 1940/4885EGFR 4466/4885
US-20240262806-A1 INHIBITORS OF NLRP3 NLRP3, NOD1, NLRP1 TRPV4 1686/4885AR 2976/4885EGFR 4849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.